Novo Nordisk, a global healthcare company and world leader in diabetes care headquartered in Denmark, is one of the largest manufacturers of biologics.

Its development of biopharmaceuticals has been focused on insulins, growth hormone therapy, hormone replacement therapy, and haemostasis management.

The company's leading biologics are:

NovoSeven (coagulation factor VIIa [recombinant]). Novoseven is a bypassing agent used to treat bleeding episodes and surgical bleeding in patients with hemophilia A or B, and patients with factor VII deficiency.

Norditropin (somatropin ). Norditropin is a growth hormone for the long-term treatment of patients with growth failure due to inadequate secretion of endogenous growth hormone and for replacement of endogenous growth hormone in adults with growth hormone deficiency.

Levemir (insulin detemir). Levemir is a long-acting basal insulin providing up to 24 hours of blood sugar control for people with diabetes.

NovoLog (insulin aspart). NovoLog is a rapid-acting insulin analog that works fast to cover mealtime blood glucose in people with diabetes.

*Information above taken from materials provided by Novo Nordisk